Summary: SNMMI has launched the pilot phase of the Thyroid Cancer Registry within its Radiopharmaceutical Therapy Registry platform to collect real-world data on radiopharmaceutical therapies, support research, and improve patient outcomes, with a full launch expected by the end of 2025.
Key Takeaways
- SNMMI has launched the pilot phase of the Thyroid Cancer Registry as part of its Radiopharmaceutical Therapy Registry (RaPTR) platform to collect real-world data on radiopharmaceutical therapies.
- The registry aims to support research and improve patient outcomes by expanding data collection to include thyroid cancer alongside existing registries for 177Lu-DOTATATE and 177Lu-PSMA-617.
- SNMMI is working with pilot centers to refine the registry before a full launch in late 2025, ensuring its alignment with clinical needs and enhancing patient safety in radiopharmaceutical therapy.
————————————————————————————————————————————————————————————
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has launched the pilot phase of the Thyroid Cancer Registry, an addition to its Radiopharmaceutical Therapy Registry (RaPTR) platform. The registry, officially introduced on January 30, 2025, joins existing registries focused on 177Lu-DOTATATE and 177Lu-PSMA-617.
RaPTR is designed to collect real-world data on the safety, effectiveness, and clinical use of radiopharmaceutical therapies. The expansion to include thyroid cancer aims to support research and improve patient outcomes across a broader range of cancers treated with these therapies.
“The thyroid cancer registry, and RaPTR as a whole, represents a rich resource for clinical investigation and educational opportunities,” says Orhan K. Oz, MD, PhD, professor at the University of Texas Southwestern and chair-elect of the RaPTR Registry Oversight Committee. “It will inform future clinical practice and prepare future leaders in the field, benefiting the medical and scientific communities of nuclear medicine and beyond.”
Enhancing Patient Care, Data Collection
During the pilot phase, SNMMI will work with pilot centers across the country to evaluate the registry’s functionality, streamline data collection, and ensure it aligns with clinical needs. The organization is seeking additional pilot sites to participate in this phase.
“On behalf of the RaPTR committee and all SNMMI staff who have helped make this possible, we are thrilled to launch the new radioactive iodine therapy module,” says Rustain Morgan, MD, nuclear radiologist at the University of Nebraska and chair of the RaPTR Registry Oversight Committee. “We are confident that the creation of a national thyroid therapy registry will improve both patient care and outcomes.”
SNMMI expects to complete the pilot phase for all three RaPTR registries in 2025, with a full launch planned before the end of the year. The expanded registry will serve as a resource for quality and patient safety in radiopharmaceutical therapy.